Metabolic activation of temozolomide measured in vivo using positron emission tomography.
暂无分享,去创建一个
S. Osman | P. Price | T. Jones | E. Newlands | M. Stevens | C. Brock | E. Aboagye | A. Saleem | S. Luthra | F. Brady | A. Ranicar | Gavin D Brown | G. Brown
[1] A. Gescher,et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide , 2004, Cancer Chemotherapy and Pharmacology.
[2] S. Osman,et al. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. , 2001, Cancer research.
[3] T Jones,et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Osman,et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action , 2000, The Lancet.
[5] A general method to correct PET data for tissue metabolites using a dual-scan approach. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] S. Osman,et al. On-line measurement of exhaled [11C]CO2 during PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] S. Osman,et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Grochow,et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Julian C. Matthews,et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study , 1998, Cancer Chemotherapy and Pharmacology.
[10] E S Newlands,et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.
[11] E. Newlands,et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.
[12] M. Stevens,et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. , 1995, Journal of medicinal chemistry.
[13] N. Bleehen,et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Stevens,et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.
[16] E. Newlands,et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.
[17] T. Jones,et al. Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] T J Spinks,et al. Physical performance of a positron tomograph for brain imaging with retractable septa. , 1992, Physics in medicine and biology.
[19] J B Bassingthwaighte,et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] E. Newlands,et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.
[21] N. Gibson,et al. DNA sequence specificity of guanine N7-alkylations for a series of structurally related triazenes. , 1988, Carcinogenesis.
[22] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.
[23] M. Tisdale. Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. , 1987, Biochemical pharmacology.
[24] C. G. Newton,et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. , 1984, Journal of medicinal chemistry.
[25] R A Brooks,et al. Theory of image reconstruction in computed tomography. , 1975, Radiology.